Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13517203 | 0.78 | IDO1 (0.66) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL1948725 | 0.78 | IDO1 (1.00) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL27490016 | 0.77 | IDO1 (0.67) | IDO1CYP3A4ADRA2ACYP11B1CYP11B2 | |
| SCHEMBL7505628 | 0.77 | IDO1 (0.72) | IDO1CYP3A4ADRA2A | |
| SCHEMBL26259980 | 0.77 | IDO1 (0.64) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL26259992 | 0.77 | ADRA2A (0.66) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL7503338 | 0.76 | IDO1 (0.63) | IDO1CYP3A4ADRA2AADRA2BADRA2C | |
| SCHEMBL871588 | 0.76 | IDO1 (0.63) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL1951228 | 0.76 | IDO1 (1.00) | IDO1CYP3A4ADRA2AADRA2BHPGDS | |
| SCHEMBL1902603 | 0.76 | IDO1 (1.00) | IDO1CYP3A4ADRA2AADRA2BHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3032625-B1 | FUEL CELL SEPARATOR | NISSHINBO CHEMICAL INC (JP) | 2020-01-08 | — | — | EP | disclosed |
| US-10358451-B2 | Heterocycles useful as IDO and TDO inhibitors | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| WO-2019005559-A1 | TDO2 AND IDO1 INHIBITORS | GENENTECH, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| EP-3264506-A1 | METHOD FOR PRODUCING A FUEL CELL SEPARATOR | Nisshinbo Chemical Inc. (JP) | 2018-01-03 | — | — | EP | disclosed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-2458667-B1 | FUEL CELL SEPARATOR | NISSHINBO CHEMICAL INC (JP) | 2017-05-24 | — | — | EP | disclosed |
| EP-2763223-B1 | POROUS SEPARATOR FOR FUEL CELLS | NISSHINBO CHEMICAL INC (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-8372192-B2 | Fuel cell separator | NISSHINBO CHEMICAL INC. (JP) | 2013-02-12 | — | — | US | disclosed |
| EP-2458667-A1 | FUEL CELL SEPARATOR | Nisshinbo Chemical Inc. (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20120077111-A1 | FUEL CELL SEPARATOR | NISSHINBO CHEMICAL INC. (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| CN-102083429-A | Ido inhibitors | NEWLINK GENETICS | 2011-06-01 | — | — | CN | disclosed |
| WO-2011056652-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS (US) | 2011-05-12 | — | — | WO | disclosed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
| US-7592456-B2 | Arylsulfonylnaphthalene derivatives as 5HT2A antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | MERCK SHARPE & DOHME LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | IDO1, IDO2, TDO2 | IDO1 1/4885CYP3A4 119/4885ADRA2A 2355/4885 |
| US-20190016726-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | IDO1 3/4885CYP3A4 246/4885ADRA2A 1151/4885 |
| US-10358451-B2 | Heterocycles useful as IDO and TDO inhibitors | IDO1, IDO2, TDO2 | IDO1 1/4885CYP3A4 119/4885ADRA2A 2355/4885 |
| US-20070281952-A1 | Arylsulfonylnaphthalene Derivatives As 5Ht2a Antagonists | HTR2A, HTR2C, HTR1A | IDO1 187/4885CYP3A4 415/4885ADRA2A 23/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 250/4885ADRA2A 906/4885 |
| US-10800780-B2 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | IDO1 3/4885CYP3A4 246/4885ADRA2A 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.